gdc-0927
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 9, 2015 (NCT02316509)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Estrogen receptor alphaDEGRADER
ESR1 degrader
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297758 ↗
Also known as
- gdc-0927
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02316509 | Phase 1 | Nov 9, 2015 | Genentech, Roche, Seragon Pharmaceuticals |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genentech | For profit | 1 | 1 | 1 | 2015 |
| Roche | For profit | 1 | 0 | 1 | 2015 |
| Seragon Pharmaceuticals | For profit | 1 | 0 | 1 | 2015 |
3 organizations
Page 1 / 1